psme4b Antibody

What is PSME4 and what is its role in cellular functions?

PSME4 (Proteasome Activator Subunit 4), also known as PA200, functions as a proteasome activator. It belongs to the same family as PSME1, PSME2, and PSME3, and plays a critical role in proteolytic processes within cells . Unlike the standard proteasome pathway that relies heavily on ubiquitin-tagging, PSME4 can activate alternative proteasomal degradation pathways. The protein is approximately 211 kDa in calculated molecular weight, though it often presents at approximately 140 kDa in electrophoretic analyses . Research indicates that PSME4 has significant roles in DNA repair, spermatogenesis, and emerging evidence points to its involvement in various pathological conditions including cancer development.

What applications are PSME4 antibodies most commonly used for?

PSME4 antibodies are validated and routinely employed across multiple experimental techniques, including:

Research applications typically require optimization of these protocols for specific experimental conditions and sample types.

What are the key differences between polyclonal and monoclonal antibodies against PSME4?

The choice between polyclonal and monoclonal PSME4 antibodies depends on experimental requirements:

Polyclonal PSME4 antibodies (such as those from Proteintech and Atlas Antibodies) are:

• Generated in rabbits using peptide immunogens

• Recognize multiple epitopes on the PSME4 protein

• Often provide higher sensitivity due to multiple epitope binding

• May show batch-to-batch variation

• Typically purified via antigen affinity chromatography

Monoclonal antibodies (though not specifically seen in these search results for PSME4):

• Would recognize a single epitope

• Offer higher specificity and reproducibility

• Would be useful for distinguishing closely related isoforms or specific domains

• Would provide consistent results across experiments

The selection should be guided by the specific research question, with polyclonal antibodies offering broader detection capacity and monoclonals offering higher specificity.

How is PSME4 implicated in cancer progression, particularly in hepatocellular carcinoma?

Research has revealed critical roles for PSME4 in cancer biology, particularly in hepatocellular carcinoma (HCC). Studies have demonstrated:

• PSME4 is significantly upregulated in HCC tissues compared to adjacent normal tissues

• High PSME4 expression correlates with poor prognosis in HCC patients

• Mechanistically, PSME4 promotes HCC cell proliferation through activation of the mTOR signaling pathway

• Knockdown of PSME4 inhibits HCC cell proliferation, increases apoptosis, and alters cell cycle progression away from S phase

These findings position PSME4 as an emerging tumor marker with potential utility in early diagnosis and prognosis of HCC. Researchers investigating PSME4 in cancer contexts should consider:

• Evaluating PSME4 expression levels in relation to clinical outcomes

• Exploring connections between PSME4 and established oncogenic pathways

• Examining PSME4 as a potential therapeutic target in cancer treatment strategies

What methodological considerations are important when performing immunoprecipitation with PSME4 antibodies?

When performing immunoprecipitation with PSME4 antibodies, researchers should consider:

• Antibody amount optimization: Use 0.5-4.0 μg antibody per 1.0-3.0 mg of total protein lysate

• Lysis buffer selection: Choose buffers that maintain protein-protein interactions while effectively solubilizing membrane-associated components

• Cross-linking considerations: For transient interactions, consider using reversible cross-linking reagents

• Pre-clearing lysates: Remove proteins that non-specifically bind to beads

• Controls: Include IgG-matched controls and input samples to validate specificity

• Washing stringency: Balance between removing non-specific interactions while maintaining specific ones

• Detection method selection: Consider whether western blotting, mass spectrometry, or other techniques best suit your downstream analysis

For Co-IP experiments investigating PSME4 interactions with other proteasome components or regulatory proteins, additional optimization of salt concentration and detergent types may be necessary to preserve physiologically relevant interactions.

What are the critical considerations when interpreting PSME4 expression data in tissue samples?

When analyzing PSME4 expression in tissue samples, researchers must navigate several interpretive challenges:

• Expression heterogeneity: PSME4 expression may vary across different cell types within the same tissue sample

• Subcellular localization: Evaluate nuclear versus cytoplasmic distribution, as this may indicate different functional states

• Correlation with clinical parameters: For cancer studies, correlate expression with staging, grading, and patient outcomes

• Antibody validation: Confirm specificity using knockout/knockdown controls or peptide blocking

• Quantification methods: Use standardized scoring systems (H-score, Allred, etc.) for IHC or fluorescence intensity measurements for IF

• Reference tissue selection: Compare with appropriate normal tissues to establish baseline expression

• Technical variables: Account for differences in fixation, processing, and antigen retrieval methods

For IHC applications specifically, researchers should note that PSME4 detection in tissues like liver may require specific antigen retrieval methods, with TE buffer (pH 9.0) showing good results for PSME4 visualization in liver cancer tissue .

What are the optimal storage conditions for maintaining PSME4 antibody activity and stability?

Proper storage is critical for maintaining antibody performance over time:

Researchers should always check the manufacturer's specific recommendations, as formulations may vary slightly between vendors. Additionally, avoid repeated freeze-thaw cycles which can degrade antibody performance over time.

What controls should be included when validating PSME4 antibodies for new experimental applications?

Thorough validation requires multiple control strategies:

• Positive controls:

  • Cell lines with known PSME4 expression (HEK-293, HepG2 cells)

  • Tissues with established PSME4 expression patterns (human liver tissue)

  • Recombinant PSME4 protein at known concentrations

• Negative controls:

  • PSME4 knockout/knockdown samples for specificity verification

  • Isotype-matched control antibodies to assess non-specific binding

  • Primary antibody omission controls

• Specificity controls:

  • Peptide blocking experiments using the immunizing peptide

  • Testing across multiple applications to confirm consistent detection patterns

  • Correlation with mRNA expression data for the same samples

• Cross-reactivity assessment:

  • Testing across species when using in non-human models

  • Comparing multiple antibodies targeting different epitopes

Documentation of these validation steps is essential for publication and reproducibility purposes, particularly when applying PSME4 antibodies to novel experimental systems or techniques.

What are the best practices for optimizing Western blot protocols when detecting PSME4?

Detecting PSME4 via Western blot requires specific optimizations:

• Sample preparation:

  • Use appropriate lysis buffers that effectively solubilize nuclear and cytoplasmic proteins

  • Include protease inhibitors to prevent degradation

  • Standardize protein concentration (typically 20-50 μg total protein per lane)

• Gel selection and transfer:

  • Use 6-8% gels or gradient gels to effectively resolve the large PSME4 protein (calculated MW: 211 kDa)

  • Consider extended transfer times or specialized transfer methods for large proteins

  • Low methanol concentrations in transfer buffer may improve transfer of large proteins

• Antibody conditions:

  • Use 1:500-1:2000 dilution of primary antibody

  • Optimize blocking conditions to reduce background

  • Consider overnight incubation at 4°C for primary antibody

• Detection considerations:

  • Note that PSME4 often presents at approximately 140 kDa rather than the calculated 211 kDa

  • Use high-sensitivity detection systems for low-abundance samples

  • Include molecular weight markers that cover the appropriate range

• Troubleshooting:

  • For weak signals, increase antibody concentration or protein loading

  • For multiple bands, verify specificity with knockout controls

  • For high background, optimize blocking and washing conditions

These optimizations will help ensure reliable and reproducible detection of PSME4 in Western blot applications.

How can researchers distinguish between PSME4 isoforms or related proteasome components?

Distinguishing between closely related proteasome components requires careful experimental design:

• Antibody selection strategies:

  • Choose antibodies targeting unique regions not conserved across related proteins

  • Verify epitope specificity through sequence analysis and validation experiments

  • Consider using multiple antibodies targeting different regions of PSME4

• Molecular weight differentiation:

  • PSME4 has a calculated molecular weight of 211 kDa but typically appears at ~140 kDa

  • PSMB4 (Proteasome subunit beta type 4) has a predicted size of 29 kDa

  • Other proteasome components have distinct molecular weights that can aid identification

• Co-expression analysis:

  • Examine correlation patterns between PSME4 and other proteasome components

  • Use multi-color immunofluorescence to assess co-localization patterns

  • Quantify relative expression levels in different cellular compartments

• Knockout/knockdown validation:

  • Use siRNA, shRNA, or CRISPR approaches targeting specific isoforms

  • Confirm knockdown specificity using PCR and protein detection methods

  • Observe phenotypic consequences to confirm functional relevance

• Mass spectrometry approaches:

  • For definitive identification, consider proteomics approaches that can distinguish isoforms based on peptide sequences

  • Use immunoprecipitation followed by mass spectrometry for complex protein identification

These approaches, used in combination, can provide confident discrimination between closely related proteasome components.

What are common causes of non-specific binding when using PSME4 antibodies, and how can these be mitigated?

Non-specific binding presents significant challenges in antibody-based detection systems:

For immunohistochemistry applications specifically:

• Background reduction can be achieved through optimization of antigen retrieval methods

• For PSME4 detection in liver tissues, TE buffer pH 9.0 has shown good results, with citrate buffer pH 6.0 as an alternative

• Titration of antibody concentrations (starting with 1:50-1:500 range) is essential for optimal signal-to-noise ratio

How should researchers interpret discrepancies between PSME4 protein levels detected by different methodologies?

When faced with methodological discrepancies in PSME4 detection:

• Common discrepancy patterns:

  • Western blot vs. IHC: Different epitope accessibility due to protein folding or fixation

  • mRNA vs. protein levels: Post-transcriptional regulation affecting translation efficiency

  • Multiple antibodies showing different patterns: Epitope-specific accessibility or isoform detection

• Analytical approaches:

  • Compare experimental conditions systematically to identify variables affecting detection

  • Consider epitope exposure differences between denatured (WB) and native (IHC/IF) conditions

  • Evaluate tissue/sample processing methods that might affect protein detection

• Validation strategies:

  • Use orthogonal methods to confirm expression (e.g., mass spectrometry)

  • Perform functional assays to correlate with protein expression data

  • Utilize genetic approaches (siRNA, CRISPR) to confirm specificity

• Interpretation framework:

  • Document method-specific limitations transparently

  • Consider each method as providing complementary rather than redundant information

  • Integrate multiple datasets to develop a comprehensive understanding

• Technical considerations:

  • For IHC/IF, antigen retrieval methods significantly impact epitope accessibility

  • For WB, sample preparation methods affect protein extraction efficiency

  • For all methods, antibody clone/lot variability should be documented

How can PSME4 antibodies be leveraged in studying DNA damage response pathways?

PSME4 has emerging roles in DNA damage response mechanisms that researchers can investigate:

• Experimental approaches:

  • Co-localization studies with DNA damage markers (γ-H2AX, 53BP1) using immunofluorescence

  • Chromatin immunoprecipitation (ChIP) to assess PSME4 recruitment to damaged DNA

  • IP-MS to identify PSME4 interactors following DNA damage induction

  • Time-course analysis of PSME4 recruitment following various DNA damaging agents

• Pathway intersection analysis:

  • Evaluate PSME4 involvement in specific DNA repair pathways (HR, NHEJ, NER)

  • Assess PSME4-dependent degradation of DNA repair factors

  • Investigate connections between PSME4 and cell cycle checkpoint proteins

• Translational relevance:

  • Correlation between PSME4 expression and radiation/chemotherapy sensitivity

  • PSME4 status as a biomarker for DNA repair capacity in tumor samples

  • Therapeutic targeting potential in cancers with DNA repair deficiencies

The methodological approach should incorporate multiparametric analyses to distinguish direct versus indirect effects of PSME4 on DNA damage response pathways.

What are the emerging therapeutic implications of targeting PSME4 in cancer?

The role of PSME4 in hepatocellular carcinoma suggests broader therapeutic potential:

• Therapeutic targeting strategies:

  • Direct inhibition of PSME4 enzymatic activity

  • Disruption of PSME4 interactions with key partners

  • Targeted degradation approaches (PROTACs, molecular glues)

  • Synthetic lethality approaches in specific genetic backgrounds

• Clinical biomarker applications:

  • PSME4 expression as a prognostic indicator in multiple cancer types

  • Correlation with treatment response to standard therapies

  • Identification of patient subgroups likely to benefit from proteasome-targeting drugs

• Pathway intervention approaches:

  • Combined targeting of PSME4 and mTOR pathways based on established connections

  • Exploration of synergies with standard chemotherapeutics

  • Investigation of PSME4 in therapy resistance mechanisms

• Methodological considerations:

  • Development of highly specific inhibitors requires detailed understanding of PSME4 structure

  • Monitoring target engagement in vivo remains challenging

  • Patient stratification based on PSME4 status requires validated clinical assays

Research in this area should prioritize specificity to avoid disruption of essential proteasome functions while targeting cancer-specific vulnerabilities.